BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

Two recent analyses, published in European Urology, 6,7 claim to give a deeper insight into the clinical efficacy of intravesical BCG as compared with mitomycin C chemotherapy. The first, a ...

Sanofi, GlaxoSmithKline, Abbott Biologicals, Bilthoven Biologicals, and Bharat Biotech International Lead the Global CompetitionDublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "BCG Vaccine Global Market ...

Morales’s protocol of 6-weekly intravesical instillations of bacillus Calmette–Guerin (BCG), introduced in 1976, has survived to this date. BCG is superior to chemotherapy as an adjuvant agent ...

Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Ferring’s Adstiladrin became the first intravesical oncologic virus approved by the FDA for BCG-Unresponsive NMIBC CIS in 2023. Health Canada gave its approval a year earlier in 2022.

Options for BCG-unresponsive NMIBC have expanded dramatically in the last few years. While it used to be that options were limited to regular intravesical chemotherapy or surgery, that changed ...

Intravesical BCG therapy: Widely used for treating bladder cancer. BCG vaccine for TB prevention: Traditionally administered to infants and children. In recent years, there has been a growing ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% complete response in patients with Bacillus Calmette-Guérin-unresponsive ...